Novartis Offers $120 Million For Corthera Eyeing Phase III Acute Cardiology Product
This article was originally published in The Pink Sheet Daily
Executive Summary
Relaxin enables the pharma to expand its reach in acute cardiology as its mega-drug Diovan faces patent expiries.
You may also be interested in...
Ranbaxy’s Ongoing Issues With FDA Continue Novartis Windfall With Diovan
Ranbaxy’s newest manufacturing site at Mohali, India, is prohibited by FDA from shipping products to the U.S., further delaying approval of generic valsartan. Novartis has recently revised its sales guidance due to lower than expected generic sales erosion in the U.S. this year.
Despite Challenges, Congestive Heart Failure Draws A Crowd
Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.
Despite Challenges, Congestive Heart Failure Draws A Crowd
Biopharma companies are drawn to CHF, despite the lack of effective biomarkers and the need for large, expensive trials.